| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/16/2013 | CA2555036C Antithrombotic compound |
| 04/16/2013 | CA2554919C Use of methylene amide derivatives in cardiovascular disorders |
| 04/16/2013 | CA2553887C Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide |
| 04/16/2013 | CA2550256C Topical formulations comprising a 1-n-arylpyrazole derivative and a formamidine |
| 04/16/2013 | CA2548273C Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| 04/16/2013 | CA2545582C 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| 04/16/2013 | CA2545133C Use of glucosidase inhibitors for therapy of mucovisidosis |
| 04/16/2013 | CA2541090C Use of indole acetic acid or derivatives thereof to increase igf-1 serum levels |
| 04/16/2013 | CA2538755C Granular jelly drink capable of masking bitterness |
| 04/16/2013 | CA2500461C Antiseptic solutions containing silver chelated with polypectate and edta |
| 04/16/2013 | CA2486157C Opioid and opioid-like compounds and uses thereof |
| 04/16/2013 | CA2484512C Treatment of cataracts and other ophthalmic diseases |
| 04/16/2013 | CA2475968C A coating for implantable medical devices to control drug elution from abasecoat |
| 04/16/2013 | CA2465973C Posh nucleic acids, polypeptides and related methods |
| 04/16/2013 | CA2431521E Steroid hormone products and methods for preparing them |
| 04/16/2013 | CA2419284C Prna chimera |
| 04/16/2013 | CA2379087C Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 04/16/2013 | CA2361246C Identification of specific differentially expressed antigens |
| 04/13/2013 | CA2776651A1 Tricyclo-phosphorothioate dna |
| 04/11/2013 | WO2013052943A2 Small molecule inhibitors of mcl-1 and uses thereof |
| 04/11/2013 | WO2013052899A1 Therapeutic sulfated polysaccharides, compositions thereof, and methods for treating patients |
| 04/11/2013 | WO2013052889A1 Nasal delivery mechanism for prophylactic and post-acute use for progesterone and/or its enantiomer for use in treatment of mild traumatic brain injuries |
| 04/11/2013 | WO2013052869A1 Treatment of rhinitis |
| 04/11/2013 | WO2013052849A2 Prophylactic and post-acute use of progesterone to better outcomes associated with concussion |
| 04/11/2013 | WO2013052787A2 Membrane activated chelators and use in the prevention and treatment of parasitic infection |
| 04/11/2013 | WO2013052765A1 Malignant and non-malignant disease treatment with ras antagonists |
| 04/11/2013 | WO2013052760A1 Compositions for the treatment of dry eye |
| 04/11/2013 | WO2013052736A2 Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
| 04/11/2013 | WO2013052727A1 Methods of treatment using modulators of sirt2 |
| 04/11/2013 | WO2013052719A1 Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature |
| 04/11/2013 | WO2013052716A1 Fatty acid synthase inhibitors |
| 04/11/2013 | WO2013052700A1 Novel sulfonamides |
| 04/11/2013 | WO2013052699A2 Novel quinoxaline inhibitors of pi3k |
| 04/11/2013 | WO2013052681A1 Methods and compositions for regulating hiv infection |
| 04/11/2013 | WO2013052652A1 Methods and systems for identifying and treating anti-progestin sensitive tumors |
| 04/11/2013 | WO2013052647A2 Formulations and uses of retinoic acid receptor selective agonists |
| 04/11/2013 | WO2013052613A1 Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication |
| 04/11/2013 | WO2013052608A1 Optically pure apogossypolone derivatives as pan-active inhibitors of anti-apoptotic bcl-2 family proteins |
| 04/11/2013 | WO2013052575A1 Methods for treating a stroke-related sensorimotor impairment using aminopyridines |
| 04/11/2013 | WO2013052550A2 Novel imidazole quinoline-based immune system modulators |
| 04/11/2013 | WO2013052465A1 [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer |
| 04/11/2013 | WO2013052433A2 Methods and compositions for reducing food intake and body weight gain in animals |
| 04/11/2013 | WO2013052395A1 1,3-substituted azetidine pde10 inhibitors |
| 04/11/2013 | WO2013052369A1 Novel benzimidazole derivatives |
| 04/11/2013 | WO2013052362A1 Hepatitis c virus inhibitors |
| 04/11/2013 | WO2013052164A1 Organonitro thioether compounds and medical uses thereof |
| 04/11/2013 | WO2013052162A1 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells |
| 04/11/2013 | WO2013052157A1 Crystalline forms of afatinib di-maleate |
| 04/11/2013 | WO2013052117A1 Choline composition |
| 04/11/2013 | WO2013052019A1 Production method for effervescent formulations comprising diclofenac |
| 04/11/2013 | WO2013052012A1 Cationic peptidopolysaccharides with excellent broad- spectrum antimicrobial activities and high selectivity |
| 04/11/2013 | WO2013052010A1 Antibiotic composition and its uses |
| 04/11/2013 | WO2013052006A1 Parp-1 inhibitors |
| 04/11/2013 | WO2013051994A1 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
| 04/11/2013 | WO2013051928A1 Treatment of eosinophilic esophagitis |
| 04/11/2013 | WO2013051904A2 Composition for preventing and treating vision deterioration and age-related macular degeneration through retinal repair using ginseng/red ginseng extracts and ginsenoside |
| 04/11/2013 | WO2013051883A2 Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein |
| 04/11/2013 | WO2013051778A1 Conjugate having tumor selectivity for targeted treatment |
| 04/11/2013 | WO2013051765A1 1-(5-bromo-2-hydroxy-4-methoxyphenyl)ethanone having anti-inflammatory effects and pharmaceutical composition containing same |
| 04/11/2013 | WO2013051728A1 Agent for improving quality of sleep |
| 04/11/2013 | WO2013051727A1 Agent for improving quality of sleep |
| 04/11/2013 | WO2013051672A1 Medicinal agent comprising thiazolidine derivative or salt thereof as active ingredient |
| 04/11/2013 | WO2013051639A1 Pyrazoloquinoline derivative |
| 04/11/2013 | WO2013051632A1 Nitrogen-containing fused heterocyclic compound |
| 04/11/2013 | WO2013051597A1 Cephem derivative having catechol group |
| 04/11/2013 | WO2013051562A1 Mouse mating inducer, mouse mating promotion method, and rodent trapping method |
| 04/11/2013 | WO2013051531A1 Novel anti-hcv agent |
| 04/11/2013 | WO2013051459A1 Promoter capable of promoting inhibition of expression of mrna by rna interference, and use thereof |
| 04/11/2013 | WO2013051435A1 Therapeutic agent, gene therapy agent, and method for preventing invasion of eosinophil |
| 04/11/2013 | WO2013051414A1 Pyrroloquinoline quinone alcohol adduct |
| 04/11/2013 | WO2013051389A1 Medicinal agent responsive to metal salen complex compound, and system for controlling in vivo behavior of metal salen complex compound |
| 04/11/2013 | WO2013051363A1 Magnetic composition, and method for producing same |
| 04/11/2013 | WO2013051330A1 Treatment of atrial fibrillation by means of vidarabine |
| 04/11/2013 | WO2013051266A1 Tau aggregation inhibitor |
| 04/11/2013 | WO2013051159A1 Nop receptor antagonist |
| 04/11/2013 | WO2013050996A2 Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| 04/11/2013 | WO2013050987A1 Carbamate/ urea derivatives containing piperidin and piperazin rings as h3 receptor inhibitors |
| 04/11/2013 | WO2013050960A1 Gluten-free food composition and food products prepared therefrom |
| 04/11/2013 | WO2013050947A1 Composition comprising bacillus calmette guerin with cox2 selective/preferential inhibitor and uses thereof |
| 04/11/2013 | WO2013050938A1 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| 04/11/2013 | WO2013050930A1 Development of a red clover phytoestrogen product for the prevention or treatment of osteoporosis |
| 04/11/2013 | WO2013050884A1 Process for the preparation of lersivirine |
| 04/11/2013 | WO2013050874A1 Pharmaceutical methods and topical compositions containing acitretin |
| 04/11/2013 | WO2013050757A1 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors |
| 04/11/2013 | WO2013050756A1 L-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p3i map kinase inhibitors |
| 04/11/2013 | WO2013050644A1 Enantiomers of 2-hydroxy derivatives of fatty acids |
| 04/11/2013 | WO2013050637A1 Oxoisoaporphine nanocapsules for treating depression |
| 04/11/2013 | WO2013050625A1 Antiviral efficacy of disodium 2,6-dimethyl-1,4-dihydropyridine-3,5-bis(carbonyloxyacetate) and its derivatives |
| 04/11/2013 | WO2013050539A2 Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |
| 04/11/2013 | WO2013050527A1 Quinazoline derivatives as pde10a enzyme inhibitors |
| 04/11/2013 | WO2013050508A1 Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors |
| 04/11/2013 | WO2013050476A1 New apoptosis inducing compounds |
| 04/11/2013 | WO2013050460A1 Ethynyl derivatives as metabotropic glutamate receptor modulators |
| 04/11/2013 | WO2013050454A1 Ethynyl derivatives as mglur5 allosteric modulators |
| 04/11/2013 | WO2013050448A1 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| 04/11/2013 | WO2013050446A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| 04/11/2013 | WO2013050438A1 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. |
| 04/11/2013 | WO2013050426A1 Carbonic anhydrase inhibitor comprising a dithiocarbamate |
| 04/11/2013 | WO2013050424A1 NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF |
| 04/11/2013 | WO2013050422A1 Reactivation of hiv-1 gene expression to treat persistent hiv infection |